MedTrace Logo

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

NCT05171530 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-12-29

No results posted yet for this study

Summary

The goal of this clinical trial is to study the safety and efficacy of lenvatinib combined with single-agent taxanes therapy in patients with HER2-negative advanced gastric cancer that have failed at the standard first-line therapy.

Conditions

  • HER2-negative Advanced Gastric Cancer

Interventions

DRUG

Lenvatinib plus taxane drugs

* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX * Drug: Docetaxel Dose: 75mg/m2 Other Name: FA * Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Yan Shi · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-05
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171530 on ClinicalTrials.gov